{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T04:37:45Z","timestamp":1787891865210,"version":"build-2784847793"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2023,6,25]],"date-time":"2023-06-25T00:00:00Z","timestamp":1687651200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2023,6,25]],"date-time":"2023-06-25T00:00:00Z","timestamp":1687651200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dermatol Ther (Heidelb)"],"published-print":{"date-parts":[[2023,8]]},"DOI":"10.1007\/s13555-023-00961-9","type":"journal-article","created":{"date-parts":[[2023,6,25]],"date-time":"2023-06-25T15:01:32Z","timestamp":1687705292000},"page":"1817-1830","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Acne Among Japanese Patients with Atopic Dermatitis Receiving Upadacitinib in the Phase\u00a03 Rising\u00a0Up Study"],"prefix":"10.1007","volume":"13","clinical-trial-number":[{"clinical-trial-number":"nct03661138","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Nobukazu","family":"Hayashi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masanori","family":"Ikeda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eliza","family":"Raymundo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingyi","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takuya","family":"Sasaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenshi","family":"Yamasaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,6,25]]},"reference":[{"key":"961_CR1","doi-asserted-by":"publisher","first-page":"2151","DOI":"10.1016\/S0140-6736(21)00588-2","volume":"397","author":"E Guttman-Yassky","year":"2021","unstructured":"Guttman-Yassky E, Teixeira HD, Simpson EL, et al. Once-daily upadacitinib versus placebo in adolescents and adults with moderate-to-severe atopic dermatitis (Measure Up 1 and Measure Up 2): results from two replicate double-blind, randomised controlled phase\u00a03 trials. Lancet. 2021;397:2151\u201368.","journal-title":"Lancet"},{"key":"961_CR2","doi-asserted-by":"publisher","first-page":"2169","DOI":"10.1016\/S0140-6736(21)00589-4","volume":"397","author":"K Reich","year":"2021","unstructured":"Reich K, Teixeira HD, de Bruin-Weller M, et al. Safety and efficacy of upadacitinib in combination with topical corticosteroids in adolescents and adults with moderate-to-severe atopic dermatitis (AD Up): results from a randomised, double-blind, placebo-controlled, phase\u00a03 trial. Lancet. 2021;397:2169\u201381.","journal-title":"Lancet"},{"key":"961_CR3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41572-018-0001-z","volume":"4","author":"S Weidinger","year":"2018","unstructured":"Weidinger S, Beck LA, Bieber T, Kabashima K, Irvine AD. Atopic dermatitis. Nat Rev Dis Primers. 2018;4:1.","journal-title":"Nat Rev Dis Primers"},{"key":"961_CR4","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1038\/s41573-021-00266-6","volume":"21","author":"T Bieber","year":"2022","unstructured":"Bieber T. Atopic dermatitis: an expanding therapeutic pipeline for a complex disease. Nat Rev Drug Discov. 2022;21:21\u201340.","journal-title":"Nat Rev Drug Discov"},{"key":"961_CR5","doi-asserted-by":"publisher","first-page":"1906","DOI":"10.3390\/jcm10091906","volume":"10","author":"M Furue","year":"2021","unstructured":"Furue M, Furue M. Interleukin-31 and pruritic skin. J Clin Med. 2021;10:1906.","journal-title":"J Clin Med"},{"key":"961_CR6","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1186\/s41927-018-0031-x","volume":"2","author":"JM Parmentier","year":"2018","unstructured":"Parmentier JM, Voss J, Graff C, et al. In vitro and in vivo characterization of the JAK1 selectivity of upadacitinib (ABT-494). BMC Rheumatol. 2018;2:23.","journal-title":"BMC Rheumatol"},{"key":"961_CR7","doi-asserted-by":"crossref","first-page":"S1015","DOI":"10.1002\/acr.21944","volume":"65","author":"J Voss","year":"2013","unstructured":"Voss J, Graff C, Schwartz A, et al. Pharmacodynamics of a novel Jak1 selective inhibitor in rat arthritis and anemia models and in healthy human subjects. Arthritis Rheumatol. 2013;65:S1015.","journal-title":"Arthritis Rheumatol"},{"key":"961_CR8","unstructured":"Rinvoq\u00ae (upadacitinib) [package insert]. AbbVie Inc., October 2022. https:\/\/www.rxabbvie.com\/pdf\/rinvoq_pi.pdf. Accessed 18 Oct 2022."},{"key":"961_CR9","unstructured":"Rinvoq\u00ae Tablets [package insert]. AbbVie GK, August 2021. Accessed 20 Oct 2022."},{"key":"961_CR10","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1001\/jamadermatol.2022.0029","volume":"158","author":"EL Simpson","year":"2022","unstructured":"Simpson EL, Papp KA, Blauvelt A, et al. Efficacy and safety of upadacitinib in patients with moderate to severe atopic dermatitis: analysis of follow-up data from the Measure Up 1 and Measure Up 2 randomized clinical trials. JAMA Dermatol. 2022;158:404\u201313.","journal-title":"JAMA Dermatol"},{"key":"961_CR11","doi-asserted-by":"publisher","first-page":"784","DOI":"10.1016\/j.jaad.2022.06.012","volume":"87","author":"P Mendes-Bastos","year":"2022","unstructured":"Mendes-Bastos P, Ladizinski B, Guttman-Yassky E, et al. Characterization of acne associated with upadacitinib treatment in patients with moderate-to-severe atopic dermatitis: a post hoc integrated analysis of 3 phase\u00a03 randomized, double-blind, placebo-controlled trials. J Am Acad Dermatol. 2022;87:784\u201391.","journal-title":"J Am Acad Dermatol"},{"key":"961_CR12","doi-asserted-by":"publisher","first-page":"2113","DOI":"10.1016\/S0140-6736(22)00581-5","volume":"399","author":"S Danese","year":"2022","unstructured":"Danese S, Vermeire S, Zhou W, et al. Upadacitinib as induction and maintenance therapy for moderately to severely active ulcerative colitis: results from three phase\u00a03, multicentre, double-blind, randomised trials. Lancet. 2022;399:2113\u201328.","journal-title":"Lancet"},{"key":"961_CR13","first-page":"44","volume":"60","author":"JM Hanifin","year":"1980","unstructured":"Hanifin JM, Rajka G. Diagnostic features of atopic dermatitis. Acta Dermatovener. 1980;60:44\u20137.","journal-title":"Acta Dermatovener"},{"key":"961_CR14","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.jdin.2021.11.001","volume":"6","author":"N Katoh","year":"2022","unstructured":"Katoh N, Ohya Y, Murota H, et al. A phase\u00a03 randomized, multicenter, double-blind study to evaluate the safety of upadacitinib in combination with topical corticosteroids in adolescent and adult patients with moderate-to-severe atopic dermatitis in Japan (Rising\u00a0Up): an interim 24-week analysis. JAAD Int. 2022;6:27\u201336.","journal-title":"JAAD Int"},{"key":"961_CR15","doi-asserted-by":"publisher","first-page":"898","DOI":"10.1111\/1346-8138.14355","volume":"45","author":"N Hayashi","year":"2018","unstructured":"Hayashi N, Akamatsu H, Iwatsuki K, et al. Japanese Dermatological Association Guidelines: guidelines for the treatment of acne vulgaris 2017. J Dermatol. 2018;45:898\u2013935.","journal-title":"J Dermatol"},{"issue":"Suppl 1","key":"961_CR16","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1111\/bjd.13462","volume":"172","author":"JK Tan","year":"2015","unstructured":"Tan JK, Bhate K. A global perspective on the epidemiology of acne. Br J Dermatol. 2015;172(Suppl 1):3\u201312.","journal-title":"Br J Dermatol"},{"key":"961_CR17","doi-asserted-by":"publisher","first-page":"890","DOI":"10.1111\/jdv.18027","volume":"36","author":"JP Thyssen","year":"2022","unstructured":"Thyssen JP, Nymand LK, Maul JT, et al. Incidence, prevalence and risk of acne in adolescent and adult patients with atopic dermatitis: a matched cohort study. J Eur Acad Dermatol Venereol. 2022;36:890\u20136.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"961_CR18","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/s13075-020-02387-6","volume":"23","author":"H Kameda","year":"2021","unstructured":"Kameda H, Takeuchi T, Yamaoka K, et al. Efficacy and safety of upadacitinib over 84 weeks in Japanese patients with rheumatoid arthritis (SELECT-SUNRISE). Arthritis Res Ther. 2021;23:9.","journal-title":"Arthritis Res Ther"},{"key":"961_CR19","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1136\/annrheumdis-2020-218870","volume":"80","author":"PJ Mease","year":"2021","unstructured":"Mease PJ, Lertratanakul A, Anderson JK, et al. Upadacitinib for psoriatic arthritis refractory to biologics: SELECT-PsA 2. Ann Rheum Dis. 2021;80:312\u201320.","journal-title":"Ann Rheum Dis"},{"key":"961_CR20","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jaad.2005.01.010","volume":"54","author":"UR Hengge","year":"2006","unstructured":"Hengge UR, Ruzicka T, Schwartz RA, Cork MJ. Adverse effects of topical glucocorticosteroids. J Am Acad Dermatol. 2006;54:1\u201315 (quiz 16-18).","journal-title":"J Am Acad Dermatol"},{"key":"961_CR21","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1001\/archderm.1972.01620150029011","volume":"106","author":"AM Kligman","year":"1972","unstructured":"Kligman AM, Mills OH Jr. Acne cosmetica. Arch Dermatol. 1972;106:843\u201350.","journal-title":"Arch Dermatol"},{"key":"961_CR22","unstructured":"PROTOPIC\u00ae (tacrolimus) ointment [package insert]. Astellas Pharma, November 2011. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2011\/050777s018lbl.pdf. Accessed 15 Mar 2023."},{"key":"961_CR23","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1007\/s40257-021-00618-3","volume":"22","author":"EL Simpson","year":"2021","unstructured":"Simpson EL, Silverberg JI, Nosbaum A, et al. Integrated safety analysis of abrocitinib for the treatment of moderate-to-severe atopic dermatitis from the phase II and phase III clinical trial program. Am J Clin Dermatol. 2021;22:693\u2013707.","journal-title":"Am J Clin Dermatol"},{"key":"961_CR24","doi-asserted-by":"publisher","first-page":"2765","DOI":"10.1007\/s13555-022-00828-5","volume":"12","author":"N Katoh","year":"2022","unstructured":"Katoh N, Takita Y, Isaka Y, Nishikawa A, Torisu-Itakura H, Saeki H. Pooled safety analysis of baricitinib in adult participants with atopic dermatitis in the Japanese subpopulation from six randomized clinical trials. Dermatol Ther (Heidelb). 2022;12:2765\u201379.","journal-title":"Dermatol Ther (Heidelb)"},{"key":"961_CR25","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1111\/1346-8138.15173","volume":"47","author":"H Nakagawa","year":"2020","unstructured":"Nakagawa H, Nemoto O, Igarashi A, et al. Long-term safety and efficacy of delgocitinib ointment, a topical Janus kinase inhibitor, in adult patients with atopic dermatitis. J Dermatol. 2020;47:114\u201320.","journal-title":"J Dermatol"},{"key":"961_CR26","doi-asserted-by":"publisher","DOI":"10.1111\/dth.14563","volume":"34","author":"SM Awad","year":"2021","unstructured":"Awad SM, Tawfik YM, El-Mokhtar MA, El-Gazzar AF, Abdel Motaleb AA. Activation of Janus kinase signaling pathway in acne lesions. Dermatol Ther. 2021;34:e14563.","journal-title":"Dermatol Ther"}],"container-title":["Dermatology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-023-00961-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13555-023-00961-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-023-00961-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,24]],"date-time":"2023-07-24T09:16:50Z","timestamp":1690190210000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13555-023-00961-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,25]]},"references-count":26,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2023,8]]}},"alternative-id":["961"],"URL":"https:\/\/doi.org\/10.1007\/s13555-023-00961-9","relation":{},"ISSN":["2193-8210","2190-9172"],"issn-type":[{"value":"2193-8210","type":"print"},{"value":"2190-9172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6,25]]},"assertion":[{"value":"5 April 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 June 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 June 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}